The Dominance of Percutaneous Biopsy (PC-LB): The Highest Volume Procedure in the US Liver Biopsy Market
Despite the rise of newer techniques, Percutaneous Liver Biopsy (PC-LB) remains the most frequently performed procedure type and holds the largest current volume share in the US Liver Biopsy Market, driven by its widespread accessibility and clinical familiarity.
PC-LB, performed using a needle inserted through the skin, typically under ultrasound guidance, is relatively simple, can be performed in outpatient settings, and requires less specialized equipment compared to transjugular or endoscopic methods. The technique is deeply embedded in clinical practice, and a high volume of physicians are trained and credentialed to perform it.
Its prevalence is supported by the fact that it is a lower-cost procedure than its alternatives when done as a standalone test, making it the default option for initial diagnosis when there are no major contraindications like severe ascites or coagulopathy. This broad accessibility ensures PC-LB continues to lead the volume count in the US Liver Biopsy Market.
FAQ
Q: What is the main guiding technology used to ensure safety and accuracy during a percutaneous liver biopsy? A: Ultrasound guidance is most commonly used to visualize the liver and the path of the biopsy needle, minimizing the risk of damage to other organs.
Q: What two key patient conditions typically serve as contraindications for performing a PC-LB? A: Severe blood clotting abnormalities (coagulopathy) and the presence of significant abdominal fluid (ascites) often necessitate the use of an alternative method like a transjugular approach.